Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zecke
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zecke is a generic formulation of abiraterone acetate, a small molecule inhibitor of the enzyme cytochrome P450 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is essential for androgen biosynthesis in the testes, adrenal glands, and prostate tumor tissues. By blocking CYP17, abiraterone acetate significantly reduces the production of testosterone and other androgens that fuel the progression of prostate cancer. Developed by Qilu Pharmaceutical, Zecke was evaluated in a bioequivalence study conducted at The Affiliated Hospital of Qingdao University, where it demonstrated bioequivalence to the reference product Zytiga. It is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and is typically administered orally in combination with prednisone.
- Brand names
- Zecke
- Other names
- abiraterone acetate
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)
Beyond the preview
Go deeper on Zecke.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zecke.